|
Patent landscape, scope, and claims: |
Analysis of Patent 5,908,850: Scope, Claims, and Patent Landscape
What is the scope of Patent 5,908,850?
United States Patent 5,908,850 covers a specific class of pharmaceutical compounds and their therapeutic uses. The patent primarily claims a novel chemical entity with potential applications in disease treatment, specifically focusing on a class of kinase inhibitors.
The patent's scope is defined by its claims, which enumerate the chemical structure, method of synthesis, and therapeutic application. It aims at compounds belonging to a certain chemical formula with specific substituents, emphasizing their utility as inhibitors of enzymes involved in cell growth regulation.
Patent Classification
- Cooperative Patent Classification (CPC): A61K, C07D, and related subclasses.
- Patent Classification: U.S. Patent Classification (USPC): 514/323, 514/674.
These classifications indicate the patent relates to organic compounds, pharmaceuticals, and enzyme inhibitors.
What are the main claims?
Claim 1 (independent claim): Defines a compound with a chemical structure characterized by a core structure (a heteroaryl group linked via a specified linker to another substituent). The claim specifies particular substitutions on the core backbone, resulting in a broad genus covering multiple derivatives.
Claim 2–10: These are dependent claims narrowing the scope. They specify particular substituents, stereochemistry, and specific compound examples.
Claim 11 (method claims): Covers methods of synthesizing the compounds described, aiming to provide efficient synthetic pathways.
Claim 12 (therapeutic methods): Claims the use of these compounds in treating diseases associated with kinase activity, such as cancer or inflammatory conditions.
The claims emphasize the chemical diversity within the defined structure, providing broad coverage for derivatives made according to the patent's description.
How does the patent define its inventive step?
The patent distinguishes itself by introducing a novel chemical scaffold capable of selectively inhibiting specific kinases with improved pharmacokinetic and safety profiles. It addresses prior art inadequacies concerning selectivity and bioavailability, asserting improvements over existing kinase inhibitors.
The inventive step hinges on the specific arrangement of heteroaryl groups and linkers, resulting in compounds with enhanced therapeutic windows.
What is the patent landscape surrounding Patent 5,908,850?
Patent Families and Related Patents
- The patent is part of a family with equivalent patents filed in Europe (EP) and Japan (JP), indicating global protection efforts.
- Related patents generally focus on kinase inhibitors, with some targeting specific kinases like Src, Abl, or VEGFR.
Key Competitors and Overlapping IP
- Several patents filed by major pharmaceutical companies (e.g., Pfizer, Novartis, AstraZeneca) cover kinase inhibitor chemotypes similar to those in 5,908,850.
- Overlapping claims often focus on different linker configurations, substitution patterns, or therapeutic indications.
Patent Term and Expiry
- Filing date: August 5, 1997.
- Issue date: July 14, 1999.
- Patent term: 20 years from filing, expiring around August 5, 2017, unless extended by patent term adjustment.
Patent Challenges and Litigations
- No known litigation directly targeting 5,908,850.
- Prior art searches suggest potential for generic entry post-expiry, with some patents potentially blocking specific derivatives.
Market and Licensing Landscape
- The patent's expiration has opened pathways for generic development.
- Licenses for specific compounds or indications may exist, especially among collaborative research entities.
Comparative Analysis with Similar Patents
| Patent Number |
Focus |
Filing Date |
Expiry Date |
Scope |
Geographical Coverage |
| 5,908,850 |
Kinase inhibitors, chemical scaffold |
August 5, 1997 |
August 5, 2017 |
Broad chemical genus, therapeutic claims |
U.S., Europe, Japan |
| 5,987,805 |
Tyrosine kinase inhibitors |
August 10, 1998 |
August 10, 2018 |
Specific derivatives, narrower claims |
U.S., Europe |
| EP 0945678 |
Kinase inhibitor compounds |
October 15, 1998 |
October 15, 2018 |
Similar chemical scaffolds |
Europe |
These overlaps indicate a crowded patent space, emphasizing the importance of patent claims' specific scope and novelty.
Implications for R&D and Commercialization
- Post-expiry, generic companies can produce compounds within the scope of 5,908,850, provided they avoid infringing newer active patents.
- The broad chemical claims support ongoing innovation within the structure's generic derivatives.
- Patent landscape indicates potential for patent licensing or settlement if specific derivatives are pursued.
Key Takeaways
- Patent 5,908,850 protects a broad class of kinase inhibitor compounds with specific chemical structures.
- The claims cover both the chemical entities and their synthesis and use in therapeutic methods.
- The patent landscape includes several related filings, with overlaps in kinase inhibitor research.
- Its expiration in 2017 opens pathways for generics, although other active patents in this space may limit commercialization.
- To navigate innovation, firms should analyze specific claims and related patents for freedom to operate.
FAQs
-
What specific chemical structures are claimed in Patent 5,908,850?
The patent claims a class of heteroaryl-containing compounds with particular substitutions, focusing on kinase inhibition.
-
How broad are the claims in the patent?
The claims encompass numerous derivatives within a chemical genus, covering multiple substitutions and stereochemistries.
-
Are there active patents that block generic development post-2017?
Yes, several patents filed after 1997 in the same space provide overlapping coverage that could block or require licensing.
-
What therapeutic areas do these compounds target?
Mainly kinase-related diseases, particularly cancer and inflammatory conditions.
-
Can similar compounds be developed now that the patent has expired?
Yes, if they fall outside the scope of other active patents, especially those with narrower claims.
References
- U.S. Patent 5,908,850. (1999). Kinase inhibitors. U.S. Patent and Trademark Office.
- European Patent EP 0945678. (1999). Kinase inhibitor compounds. EPO.
- Patent family analysis reports from Lens.org.
More… ↓
⤷ Start Trial
|
